Theratechnologies Inc (TH) Price Target Cut to C$9.25

Theratechnologies Inc (TSE:TH) had its price objective dropped by equities researchers at Scotiabank from C$10.00 to C$9.25 in a research report issued to clients and investors on Friday. The brokerage presently has an “outperform” rating on the stock. Scotiabank’s price objective indicates a potential upside of 17.68% from the stock’s previous close.

Separately, National Bank Financial lifted their price target on shares of Theratechnologies from C$9.25 to C$9.75 and gave the company an “outperform” rating in a research note on Friday.

Theratechnologies (TSE:TH) traded up 1.53% during trading on Friday, hitting $7.98. 25,790 shares of the stock traded hands. The company’s market capitalization is $593.83 million. Theratechnologies has a one year low of $2.61 and a one year high of $8.72. The company’s 50 day moving average is $7.55 and its 200 day moving average is $7.18.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://ledgergazette.com/2017/10/08/theratechnologies-inc-th-pt-lowered-to-c9-25.html.

Theratechnologies Company Profile

Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal

Separately, National Bank Financial lifted their price target on shares of Theratechnologies from C$9.25 to C$9.75 and gave the company an “outperform” rating in a research note on Friday.

Theratechnologies (TSE:TH) traded up 1.53% during trading on Friday, hitting $7.98. 25,790 shares of the stock traded hands. The company’s market capitalization is $593.83 million. Theratechnologies has a one year low of $2.61 and a one year high of $8.72. The company’s 50 day moving average is $7.55 and its 200 day moving average is $7.18.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://ledgergazette.com/2017/10/08/theratechnologies-inc-th-pt-lowered-to-c9-25.html.

Theratechnologies Company Profile

Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.

Receive News & Ratings for Theratechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply